# ALTER-L043 (NCT05351788)

> SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05351788
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Non-small Cell Lung Cancer
- Interventions: SKB264; KL-A167; Carboplatin; Cisplatin
- Enrollment: 110
- Primary outcome: Incidence and severity of adverse events (AEs)
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on ALTER-L043 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=alter-l043-nct05351788